ALGS Cuts Loss by 76% as Revenue Plummets 73%

Aligos (ALGS) reported its fiscal 2025 Q4 earnings on March 5, 2026, showcasing a dramatic 75.8% reduction in net loss to -$19.88 million from -$82.15 million in 2024 Q4, despite a 73.1% revenue drop. The company’s shares, however, faced downward pressure, tumbling 16.23% month-to-date.

Revenue

Aligos’ total revenue plummeted to $169,000 in 2025 Q4, a stark 73.1% decline from $629,000 in 2024 Q4. This contraction reflects ongoing challenges in monetizing its pipeline of liver and viral disease therapies, though the company remains focused on clinical advancements.

Earnings/Net Income

The company narrowed its per-share loss to -$3.23 in 2025 Q4 from -$21.26 in 2024 Q4, marking a 84.8% improvement. This significant narrowing of the loss underscores operational efficiency gains, though the net loss remains substantial at -$19.88 million.

Price Action

Aligos’ stock underperformed in the short term, with a 2.06% single-day drop, an 11.20% weekly decline, and a 16.23% monthly slump. The stock’s volatility highlights investor skepticism despite earnings improvements.

Post-Earnings Price Action Review

A strategy of buying Aligos shares on earnings release dates and selling 30 days later delivered a 78.03% return over three years, outperforming the 56.25% benchmark by 21.77%. While the approach demonstrated resilience—evidenced by a 0.21 Sharpe ratio and 84.83% maximum drawdown—the high 73.37% volatility underscores the risks of relying on earnings-driven market reactions. This strategy’s success, however, may be contingent on continued positive post-earnings momentum.

CEO Commentary

The CEO highlighted progress in narrowing the net loss and advancing key pipeline candidates, including Pevifoscorvir sodium in Phase 2 trials for hepatitis B. Emphasizing operational efficiency, the CEO noted the company’s focus on accelerating clinical data while managing costs.

Guidance

Aligos expects topline data from its Phase 2 B-SUPREME study for Pevifoscorvir sodium in 2027, with interim results from 36 HBeAg-negative and 55 HBeAg-positive patients already reached in Q4 2025 and January 2026, respectively. The company remains committed to advancing its liver and viral disease portfolio despite near-term financial pressures.

Additional News

Analysts from H.C. Wainwright and UBS reiterated “Buy” ratings for Aligos, with price targets of $50 and $20, respectively. Lucid Capital Markets also joined with a $36 price target in early 2025. Despite recent stock declines, the firm’s pipeline progress and narrowing losses have attracted renewed institutional interest, though execution risks remain.

[Generated Title]

[Existing Article Opener]

[New 70-word Paragraph]

Aligos (ALGS) reported a 75.8% reduction in net loss for 2025 Q4, narrowing the deficit to $19.88 million from $82.15 million in 2024 Q4. However, revenue plummeted 73.1% to $169,000, reflecting ongoing commercialization challenges. The company’s stock, down 16.23% month-to-date, faces pressure despite improved earnings, as investors weigh progress against financial sustainability.

[Revenue]

[Earnings/Net Income]

[Price Action]

[Post Earnings Price Action Review]

[CEO Commentary]

[Guidance]

[Additional News]